Compass Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on the stock and has a $10.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Zhu has given his Buy rating due to a combination of factors surrounding Compass Therapeutics’ promising clinical trial data and strategic enrollment strategies. The upcoming Phase 2/3 COMPANION-002 trial results are anticipated to show strong progression-free survival (PFS) for the combination of tovecimig and paclitaxel, suggesting a significant advantage over paclitaxel alone. Zhu’s analysis includes a detailed bottom-up estimate of PFS, which points to a favorable outcome for the trial.
Additionally, Zhu’s confidence is bolstered by the enrollment model, which indicates a robust recruitment process, with the majority of patients enrolled within a specific timeframe, enhancing the reliability of the trial results. The expected overall survival (OS) outcomes are projected to exceed historical control arms, indicating a potential meaningful separation from the control group. These factors, combined with the company’s financial stability, support Zhu’s optimistic outlook and Buy rating for Compass Therapeutics.